Helomics™ Corporation, Med BioGene’s partner responsible for the commercialization of GeneFx™ Lung, has announced that Neil Campbell, their President and Chief Executive Officer, will provide an overview of the personalized healthcare landscape, the Company’s business, and it’s comprehensive tumorprofiling technologies. The presentation will take place at the “Personalized Medicine World Conference” to be held in Oxford, UK between April 15th and 17th, 2015.

Helomics™ Corporation is a privately held personalized healthcare company that provides comprehensive tumor profiling utilizing proprietary live cell and fixed cell products and services. Helomics™ entered into an agreement with Med BioGene Inc. in 2011 to license and commercialize MBI’s GeneFx™ Lung product.

For further information visit www.helomics.com